Market Currents
Cepheid (CPHD) guides Q3 sales lower, saying revenue is expected to be in the range of $79M to...
-
Wednesday, September 26, 2012, 4:37 PM ETCepheid (CPHD) guides Q3 sales lower, saying revenue is expected to be in the range of $79M to $81M, lower than targeted due to intermittent interruptions in the supply of Xpert cartridge parts. The parts availability is being addressed and Cepheid is working aggressively to ship orders. However, the company currently expects to exit the quarter with more than $5M in backorders which it expects to be fulfilled by the end of October. Shares -3% AH.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
This news story has 1 comment:
I'm a retired ceramic engineer, and my wife and I (she's an RN) are both interested in biotechnology, especially if we can learn more about CPHD without having to get sick to do that. BTW we own only a modest amount of CPHD. (We've been considering buying Ohio before Nov 6th.)
Let's get a conversation going here.